# IHCP *bulletin*

## IHCP removes coverage for voxelotor (Oxbryta)

Effective immediately, for dates of service (DOS) on or after Oct. 2, 2024, the Indiana Health Coverage Programs (IHCP) pharmacy benefit will no longer reimburse claims for voxelotor (Oxbryta).

On Sept. 26, 2024, the U.S. Food and Drug Administration (FDA) published an alert about the voluntary withdrawal of Oxbryta from the market by the drug's manufacturer, Pfizer Inc. In the FDA alert, the manufacturer recommends, "Health care professionals should stop prescribing Oxbryta. Patients and caregivers should contact their health care professional about stopping Oxbryta and starting another treatment option."

### Carve out

Oxbryta has been carved out from managed care, which means that prior authorization (PA) and claims were processed through the fee-for-service (FFS) pharmacy benefit administrator, Optum Rx, for all IHCP members.

### Additional information

Questions about this bulletin and carved-out drugs should be directed to the Optum Rx Clinical and Technical Help Desk at 855-577-6317.

Individual managed care entities (MCEs) establish and publish billing and reimbursement information within the managed care delivery system. Questions about managed care billing and reimbursement should be directed to the MCE with which the member is enrolled.

### QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 800-457-4584.

### COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the *IHCP Bulletins* page of the IHCP provider website at in.gov/medicaid/providers.

### SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the IHCP provider website at in.gov/medicaid/providers.